Hand size and growth in untreated and IGF-I treated patients with Laron syndrome

J Pediatr Endocrinol Metab. 2009 Mar;22(3):235-9. doi: 10.1515/jpem.2009.22.3.235.

Abstract

We have previously reported on the linear growth, growth of the head circumference and foot length in untreated and IGF-I treated patients with Laron syndrome (LS) (primary GH insensitivity).

Aim: To assess the size and growth of the hands in patients with LS from early childhood to adult age.

Patients: Ten IGF-I treated children with LS (4 M, 6 F) and 24 untreated patients (10 M, 14 F) were studied.

Methods: Measurements of palm length were made on available standardized hand X-rays from infancy to adult age. The measurements were compared to normal references and SD values were calculated for each measurement. The growth of the hand was compared to the concomitant height of the body.

Results: Hand SDS in untreated patients with LS decreased with age, from a mean of -2.8 +/- 0.7 (age 1-3 years) to -7.3 +/- 0.8 (age 13-15 years) and to -9.0 +/- 3.9 (age 40-50 years). During 9 years of IGF-I treatment the hand size deficit SDS did not improve in contradistinction to the height SDS which decreased from -6.2 +/- 1.2 to -3.9 +/- 0.5.

Conclusion: Congenital IGF-I deficiency, as in Laron syndrome, profoundly affects the size and growth of the hand as part of its growth retardation characteristics, resulting in acromicria.

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Female
  • Hand / diagnostic imaging
  • Hand / growth & development*
  • Hand / pathology
  • Humans
  • Infant
  • Insulin-Like Growth Factor I / therapeutic use*
  • Laron Syndrome / diagnosis
  • Laron Syndrome / drug therapy*
  • Laron Syndrome / physiopathology
  • Male
  • Middle Aged
  • Radiography
  • Recombinant Proteins / therapeutic use
  • Treatment Outcome
  • Young Adult

Substances

  • Recombinant Proteins
  • Insulin-Like Growth Factor I